Picard Medical

Picard Medical FCF Yield

The Free Cash Flow Yield of Picard Medical (PMI) as of Nov 12, 2026 is -13.63 %. In the previous year, Free Cash Flow Yield was -10.33 % — a change of 31.99% (lower).

FCF Yield

-13.63 %

YoY

31.99%

Last updated:

Free Cash Flow Yield of Picard Medical is 2025 -13.63 % . Free Cash Flow Yield of Picard Medical was 2024 -10.33 % . It decreases by 31.99% lower compared to the previous year.

The Picard Medical FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2022
-9.35 USD
Jan 1, 2023
-9.26 USD
Jan 1, 2024
-10.33 USD
Jan 1, 2025
-13.63 USD
The Picard Medical FCF Yield history
YEARFCF YieldYoY
-13.63 %+31.99%
-10.33 %+11.59%
-9.26 %-1.03%
-9.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Picard Medical Stock analysis

What does Picard Medical do? Picard Medical Inc generates revenue through its wholly-owned subsidiary SynCardia Systems, LLC, which produces and sells the SynCardia TAH, the only FDA and Health Canada-approved implantable total artificial heart. The product consists of an implantable device, an external pneumatic driver, and drivelines connecting them, designed for biventricular heart replacement. Hospitals and cardiac care centers purchase these systems for patients with end-stage heart failure requiring temporary or permanent heart replacement. The company's revenue model relies on direct sales of the SynCardia TAH system to healthcare institutions specializing in advanced cardiac treatments. SynCardia Systems, LLC focuses on the medical technology segment within the health care equipment and supplies industry, targeting hospitals and medical facilities that perform complex cardiac procedures. The SynCardia TAH is marketed as a life-saving solution for patients with severe heart conditions, with no competing FDA-approved alternatives. The company's revenue stream is derived from the sale of the complete system, including the implant, driver, and drivelines, to healthcare providers who serve patients in critical cardiac care scenarios. The SynCardia TAH system is the sole product line of SynCardia Systems, LLC, with no other medical devices or services offered by the subsidiary. Picard Medical Inc's business model centers on the exclusive distribution of this FDA-approved artificial heart, which is used in both temporary and permanent heart replacement cases. The company's revenue is generated solely through the sale of the SynCardia TAH system to hospitals and cardiac care centers that specialize in treating end-stage heart failure patients. Picard Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Picard Medical stock

Free Cash Flow Yield of Picard Medical is -13.63 % in 2025.

Free Cash Flow Yield of Picard Medical changed from -10.33 % to -13.63 %, representing a 31.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Picard Medical since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Picard Medical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Picard Medical

All Key Metrics — Picard Medical